Discussion
The U.S. Food and Drug Administration (FDA) will hear directly from people living with Charcot-Marie-Tooth disease type 2C (CMT2C) during an upcoming virtual meeting organized by the Charcot-Marie-Tooth Association (CMTA). The 90-minute patient listening session, scheduled for Oct. 20, will give patients, caregivers, and medical experts an…